

Docket No.: 220051US0

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313



RE: Application Serial No.: 10/082,082
Applicants: Munetetsu TEI
Filing Date: February 26, 2002
For: ANTITUMOR AND ANTIVIRAL MEDICATIONS
AND METHOD FOR PRODUCING THE SAME
Group Art Unit: 1651
Examiner: Vera Afremova

RECEIVED
JUL - 7 2003
TECH CENTER 1600/2900

SIR:


Attached hereto for filing are the following papers:

Response to Requirement for Restriction; Request for Extension of Time (two month)

Our check in the amount of **\$205.00** is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Norman F. Obion
Registration No. 24,618



22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

Rohitha M. Jayasuriya
Registration No. 50,385

Application No. 10/082,082
Reply to Office Action of April 4, 2003



#9
23
7/8/03

DOCKET NO: 220051US0

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
MUNETETSU TEI : EXAMINER: AFREMOVA, VERA
SERIAL NO: 10/082,082 :
FILED: FEBRUARY 26, 2002 : GROUP ART UNIT: 1651
FOR: ANTITUMOR AND ANTIVIRAL :
MEDICATIONS AND METHOD FOR
PRODUCING THE SAME

RECEIVED
JUL - 7 2003
TECH CENTER 1600/2900

RESPONSE TO REQUIREMENT FOR RESTRICTION

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Official Action of April 4, 2003, Applicants elect, with traverse,
Group I, Claims 1-36, drawn to an antitumor and antiviral medication with activated
lymphocytes.

REMARKS

The Office has required restriction in the present application as follows:

- Group I: Claims 1-36, drawn to an antitumor and antiviral medication with activated lymphocytes;
- Group II: Claims 37 and 38, drawn to an antitumor medication consisting of reserpine derived from *Rauwolfia serpentina*;
- Group III: Claims 39-50, drawn to a method for producing antitumor and antiviral medication with activated heat treated lymphocytes;
- Group IV: Claims 51 and 52, drawn to a method for producing antitumor and antiviral medication with activated lymphocytes treated with galenical extract of crude drugs;